Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Sargramostim (Primary)
- Indications Pulmonary alveolar proteinosis
- Focus Adverse reactions
- Acronyms PharmPAP
- 31 Jul 2017 Planned initiation date changed from 15 Jul 2017 to 1 Sep 2017.
- 19 Jun 2017 Planned initiation date changed from 1 Jan 2017 to 15 Jul 2017.
- 02 Jan 2017 New trial record